Evidence map›Paper›PMID 38675826›Full record

ArticleVaccines2024

COVID-19 Vaccine Hesitancy and Associated Oral Cholera Vaccine Hesitancy in a Cholera-Endemic Country: A Community-Based Cross-Sectional Study in the Democratic Republic of Congo.

Arsene Daniel Nyalundja, Patrick Musole Bugeme, Alain Balola Ntaboba, Victoire Urbain Hatu'm, Guillaume Shamamba Ashuza, Jacques Lukenze Tamuzi, Duduzile Ndwandwe, Chinwe Iwu-Jaja, Charles Shey Wiysonge, Patrick D M C Katoto

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Arsene Daniel NyalundjaCenter for Tropical Diseases and Global Health (CTDGH), Catholic University of Bukavu (UCB), Bukavu 285, Democratic Republic of the Congo.ORCID 0000-0002-4802-3928
Patrick Musole BugemeCenter for Tropical Diseases and Global Health (CTDGH), Catholic University of Bukavu (UCB), Bukavu 285, Democratic Republic of the Congo.ORCID 0000-0001-7383-0265
Alain Balola NtabobaFaculty of Medicine, Catholic University of Bukavu (UCB), Bukavu 285, Democratic Republic of the Congo.ORCID 0009-0003-9970-8120
Victoire Urbain Hatu'mFaculty of Medicine, Catholic University of Bukavu (UCB), Bukavu 285, Democratic Republic of the Congo.
Guillaume Shamamba AshuzaFaculty of Medicine, Catholic University of Bukavu (UCB), Bukavu 285, Democratic Republic of the Congo.ORCID 0000-0003-0678-4013
Jacques Lukenze TamuziDepartment of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7505, South Africa.ORCID 0000-0003-1070-1962
Duduzile NdwandweCochrane South Africa, South African Medical Research Council, Cape Town 7501, South Africa.
Chinwe Iwu-JajaCochrane South Africa, South African Medical Research Council, Cape Town 7501, South Africa.ORCID 0000-0003-0765-7497
Charles Shey WiysongeCochrane South Africa, South African Medical Research Council, Cape Town 7501, South Africa.
Patrick D M C KatotoCenter for Tropical Diseases and Global Health (CTDGH), Catholic University of Bukavu (UCB), Bukavu 285, Democratic Republic of the Congo.
South African Medical Research Council · ZAUniversité Catholique de Bukavu · CDJohns Hopkins University · USStellenbosch University · ZA

Funding

Cochrane South Africa at the South African Medical Research Council CSASAMRC001World Health Organization 001
6 · The paper itself

Abstract

COVID-19 vaccine hesitancy and its enablers shape community uptake of non-covid vaccines such as the oral cholera vaccine (OCV) in the post-COVID-19 era. This study assessed the impact of COVID-19 vaccine hesitancy and its drivers on OCV hesitancy in a cholera-endemic region of the Democratic Republic of Congo. We conducted a community-based survey in Bukavu. The survey included demographics, intention to take OCV and COVID-19 vaccines, reasons for COVID-19 hesitancy, and thoughts and feelings about COVID-19 vaccines. Poisson regression analyses were performed. Of the 1708 respondents, 84.66% and 77.57% were hesitant to OCV alone and to both OCV and COVID-19, respectively. Hesitancy to COVID-19 vaccines rose OCV hesitancy by 12% (crude prevalence ratio, [cPR] = 1.12, 95%CI [1.03-1.21]). Independent predictors of OCV hesitancy were living in a semi-urban area (adjusted prevalence ratio [aPR] = 1.10, 95%CI [1.03-1.12]), religious refusal of vaccines (aPR = 1.06, 95%CI [1.02-1.12]), concerns about vaccine safety (aPR = 1.05, 95%CI [1.01-1.11]) and adverse effects (aPR = 1.06, 95%CI [1.01-1.12]), as well as poor vaccine literacy (aPR = 1.07, 95%CI [1.01-1.14]). Interestingly, the belief in COVID-19 vaccine effectiveness reduced OCV hesitancy by 24% (aPR = 0.76, 95%CI [0.62-0.93]). COVID-19 vaccine hesitancy and its drivers exhibited a significant domino effect on OCV uptake. Addressing vaccine hesitancy through community-based health literacy and trust-building interventions would likely improve the introduction of novel non-COVID-19 vaccines in the post-COVID-19 era.

Indexed as

immunizationnon-COVID-19 vaccineSouth Kivuvaccine misinformationVibrio cholerae

Identifiers

PMID38675826
PMCPMC11053998
OpenAlexW4395011214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.